Who
Louis Edward Tamayo
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Lexeo Therapeutics.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $82K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Aug 2025
- Last trade
- 24 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 28 Sep 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,750 at $0.00 | filing |
| 24 Sep 2026filed 28 Sep 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,750 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K4,117 at $4.91 | filing |
| 18 Aug 2026filed 19 Aug 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K4,117 at $4.91 | filing |
| 1 Jul 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K4,641 at $4.49 | filing |
| 1 Jul 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K4,641 at $4.49 | filing |
| 29 Jun 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,665 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,665 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,665 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,665 at $0.00 | filing |
| 29 Aug 2025filed 3 Sep 2025 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —280,000 at $0.00 | filing |
| 29 Aug 2025filed 3 Sep 2025 | LXEO Lexeo TherapeuticsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMLXEO · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Louis Edward Tamayo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.